Roberta Magalhães Tarantino
Research Subjects
Research Interests
Roberta Magalhães Tarantino has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Gabriella de Medeiros Abreu
Laboratory of Human Genetics, Oswaldo Cruz Institute, Oswaldo Cruz Foundation, Rio de Janeiro, Brazil
3 shared publications - Mário Campos Junior
Laboratory of Human Genetics, Oswaldo Cruz Institute, Oswaldo Cruz Foundation, Rio de Janeiro, Brazil
3 shared publications Ana Carolina Proença da Fonseca
2 shared publications- Ana Carolina Proença da Fonseca
Laboratory of Immunopharmacology, Oswaldo Cruz Institute, Oswaldo Cruz Foundation, Rio de Janeiro, Brazil
2 shared publications - Lenita Zajdenverg
Departamento de Medicina Interna, Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ, Brasil
2 shared publications - Maria de Fátima Carvalho Pereira
Universidade Federal do Tocantins
2 shared publications
Latest Publications
- Open Access
- 1 July 2020
- Published by Taylor & Francis in Diabetes, Metabolic Syndrome and Obesity
- Vol. ume 13, 2623-2631
Identification of the First PAX4-MODY Family Reported in Brazil
Purpose: The aim of this study was to sequence the coding region of the PAX4 gene in a Brazilian cohort with clinical manifestations of monogenic diabetes. Patients and Methods: This study included 31 patients with autosomal dominant history of diabetes, age at diagnosis ≤ 40 years, BMI < 30 kg/m2, and no mutations in GCK or HNF1A, HNF4A, and HNF1B. Screening of the PAX4 coding region was performed by Sanger sequencing. In silico algorithms were used to assess the potential impact of amino acid substitutions on protein structure and function. Additionally, PAX4-MODY family members and 158 control subjects without diabetes were analyzed for the identified mutation. Results: The molecular analysis of PAX4 has detected one missense mutation, p.Arg164Gln (c.491G>A), segregating with diabetes in a large Brazilian family. The mutation was absent among the control group. The index case is a woman diagnosed at 32 years of age with polyneuropathy and treated with insulin. She did not present diabetic renal disease or retinopathy. Family members with the PAX4 p.Arg164Gln mutation have a heterogeneous clinical manifestation and treatment response, with age at diagnosis ranging from 24 years to 50 years. Conclusion: To the best of our knowledge, this is the first study to report a PAX4-MODY family in Brazil. The age of PAX4-MODY diagnosis in the Brazilian family seems to be higher than the classical criteria for MODY. Our results reinforce the importance of screening large monogenic diabetes families for the understanding of the clinical manifestations of rare forms of diabetes for the specific and personalized treatment.
- 1 July 2020
- Published by Taylor & Francis in Diabetes, Metabolic Syndrome and Obesity
- Vol. ume 13, 2623-2631
Open AccessIdentification of the First PAX4-MODY Family Reported in Brazil
Purpose: The aim of this study was to sequence the coding region of the PAX4 gene in a Brazilian cohort with clinical manifestations of monogenic diabetes. Patients and Methods: This study included 31 patients with autosomal dominant history of diabetes, age at diagnosis ≤ 40 years, BMI < 30 kg/m2, and no mutations in GCK or HNF1A, HNF4A, and HNF1B. Screening of the PAX4 coding region was performed by Sanger sequencing. In silico algorithms were used to assess the potential impact of amino acid substitutions on protein structure and function. Additionally, PAX4-MODY family members and 158 control subjects without diabetes were analyzed for the identified mutation. Results: The molecular analysis of PAX4 has detected one missense mutation, p.Arg164Gln (c.491G>A), segregating with diabetes in a large Brazilian family. The mutation was absent among the control group. The index case is a woman diagnosed at 32 years of age with polyneuropathy and treated with insulin. She did not present diabetic renal disease or retinopathy. Family members with the PAX4 p.Arg164Gln mutation have a heterogeneous clinical manifestation and treatment response, with age at diagnosis ranging from 24 years to 50 years. Conclusion: To the best of our knowledge, this is the first study to report a PAX4-MODY family in Brazil. The age of PAX4-MODY diagnosis in the Brazilian family seems to be higher than the classical criteria for MODY. Our results reinforce the importance of screening large monogenic diabetes families for the understanding of the clinical manifestations of rare forms of diabetes for the specific and personalized treatment.
- Open Access
- 2 October 2019
- Published by Wiley in Molecular Genetics & Genomic Medicine
- Vol. 7 (12) , e989
The first case of NEUROD1‐MODY reported in Latin America
Background: MODY‐NEUROD1 is a rare form of monogenic diabetes caused by mutations in Neuronal differentiation 1 (NEUROD1). Until now, only a few cases of MODY‐NEUROD1 have been reported worldwide and the real contribution of mutations in NEUROD1 in monogenic diabetes and its clinical impact remain unclear.Methods: Genomic DNA was isolated from peripheral blood lymphocytes of 25 unrelated Brazilians patients with clinical characteristics suggestive of monogenic diabetes and the screening of the entire coding region of NEUROD1 was performed by Sanger sequencing.Results: We identified one novel frameshift deletion (p.Phe256Leufs*2) in NEUROD1 segregating in an autosomal dominant inheritance fashion. Almost 20 years after the first report of NEUROD1‐MODY, only a few families in Europe and Asia had shown mutations in NEUROD1 as the cause of monogenic diabetes.Conclusion: To our knowledge, we described the first case of NEUROD1‐MODY in a Latin American family.
- 2 October 2019
- Published by Wiley in Molecular Genetics & Genomic Medicine
- Vol. 7 (12) , e989
Open AccessThe first case of NEUROD1‐MODY reported in Latin America
Background: MODY‐NEUROD1 is a rare form of monogenic diabetes caused by mutations in Neuronal differentiation 1 (NEUROD1). Until now, only a few cases of MODY‐NEUROD1 have been reported worldwide and the real contribution of mutations in NEUROD1 in monogenic diabetes and its clinical impact remain unclear.Methods: Genomic DNA was isolated from peripheral blood lymphocytes of 25 unrelated Brazilians patients with clinical characteristics suggestive of monogenic diabetes and the screening of the entire coding region of NEUROD1 was performed by Sanger sequencing.Results: We identified one novel frameshift deletion (p.Phe256Leufs*2) in NEUROD1 segregating in an autosomal dominant inheritance fashion. Almost 20 years after the first report of NEUROD1‐MODY, only a few families in Europe and Asia had shown mutations in NEUROD1 as the cause of monogenic diabetes.Conclusion: To our knowledge, we described the first case of NEUROD1‐MODY in a Latin American family.
- Open Access
- 25 September 2019
- Published by Archives of Endocrinology and Metabolism in Archives of Endocrinology and Metabolism
- Vol. 64 (AHEAD) , 17-23
MODY probability calculator for GCK and HNF1A screening in a multiethnic background population
Key words: GCK; HNF1A; MODY; monogenic diabetes
- 25 September 2019
- Published by Archives of Endocrinology and Metabolism in Archives of Endocrinology and Metabolism
- Vol. 64 (AHEAD) , 17-23
Open AccessMODY probability calculator for GCK and HNF1A screening in a multiethnic background population
Key words: GCK; HNF1A; MODY; monogenic diabetes